Okay, here is the abstract and summary for the TWiV 1208 transcript.
Abstract:
This episode of This Week in Virology (TWiV 1208) features Dr. Daniel Griffin's weekly clinical update. Key topics include the concerning rise in vaccine-preventable diseases, specifically the ongoing measles outbreak with associated child fatalities and the increase in pertussis cases, alongside discussion of vaccine hesitancy and misinformation. The update covers the first human H5N1 case reported in Mexico and the typical seasonality of human metapneumovirus (hMPV). Dr. Griffin reviews current statistics for influenza, RSV, and SARS-CoV-2, noting declining trends but emphasizing continued risks and vaccination importance, including COVID booster recommendations and Novavax availability issues. Significant research findings are discussed, including a study suggesting the shingles vaccine may reduce dementia risk, a study confirming SARS-CoV-2 aerosol transmission via ventilation systems in a hospital setting, and recent trials on long COVID interventions (showing Paxlovid and Donepezil lack efficacy for treating established long COVID symptoms) and brain volume changes post-COVID. The episode also addresses listener questions on topics like penicillin allergy statistics, measles immunity, and H5N1 vaccine potential.
TWiV 1208 Clinical Update: Measles, Pertussis, H5N1, COVID, and Long COVID Insights
0:00Introduction & Perspective: Dr. Griffin opens by quoting Paul Farmer, emphasizing the importance of understanding individual suffering behind statistics, setting the stage for discussing recent disease impacts.
2:37Shingles Vaccine and Dementia Risk: Discussion of a study in Nature using a natural experiment in Wales. Findings suggest the older, live attenuated herpes zoster vaccine (Zostavax) was associated with a 20% relative reduction in new dementia diagnoses over 7 years. The effect was stronger in women. Getting antivirals quickly after breakthrough shingles further reduced dementia risk, strengthening the link between the virus and dementia.
An 8-year-old girl (Daisy) died from measles pulmonary failure in Texas, the second child death in the state.
RFK Jr.'s conflicting public statements (endorsing MMR) versus private actions (undermining vaccine confidence with grieving families) are highlighted.
US measles cases exceed 600 across 22 jurisdictions; Texas reports over 500 cases with 57 hospitalizations. Unvaccinated adults are also affected (over 100 cases >18 yrs).
Vaccine recommendations reiterated: Two MMR doses are crucial. Those receiving only one dose (common between 1971-1989) should get a second. The vaccine is safe and does not cause autism.
Two infants died from pertussis in Louisiana amid rising cases nationally, coinciding with the state halting vaccine promotion efforts.
Pertussis described: bacterial infection, classic "whoop" cough, post-tussive vomiting, can last 100+ days.
Severe risk for infants <1 year (1/3 hospitalized), especially <6 months (1% case fatality rate).
Vaccination schedule detailed: DTaP 5-dose series for children, Tdap booster for adolescents/adults, crucial Tdap dose during each pregnancy (3rd trimester), and cocooning (vaccinating close contacts).
20:52H5N1 (Bird Flu) Human Case: Mexico reported its first human case of H5N1 in a 3-year-old girl, hospitalized in serious condition.
21:15Human Metapneumovirus (hMPV): An MMWR report confirms hMPV seasonality, typically peaking in the spring as RSV and flu decline. It's highlighted as one of the "Big Four" common respiratory viruses.
23:08Polio - A Human Story: Dr. Griffin shares the story of a 74-year-old polio survivor he treated, illustrating the lifelong devastating impact of the paralytic disease contracted in childhood before widespread vaccination.
26:55Influenza Update: Flu activity is decreasing nationally, though still high in NY and ME. Sadly, 9 more pediatric flu deaths were reported, totaling 168 for the season, emphasizing the importance of flu vaccination.
28:13RSV Update: RSV activity is low nationally, suggesting the season is ending and was relatively mild.
Wastewater and CDC data show low to medium activity nationally, though some hotspots persist (e.g., higher death rates in TN, AL). Overall national trends are decreasing.
Variant tracking continues (implicitly via Nextstrain links).
29:16COVID Aerosol Transmission Study: A study using hamsters confirmed infectious SARS-CoV-2 transmission via a building's ventilation system from patient rooms to remote locations, highlighting the importance of ventilation in infection control.
CDC recommends annual vaccination, with a second dose 6 months later for those 65+.
Concerns raised about Novavax availability and uptake, potentially limiting options. Low overall booster uptake might affect future vaccine availability.
33:04COVID Treatment: Paxlovid remains the primary outpatient antiviral. A cost-effectiveness study suggests its price might need adjustment given current efficacy levels. Remdesivir, Molnupiravir, and convalescent plasma (for immunocompromised) remain options. Steroids and anticoagulation are key for hospitalized patients with hypoxia.
34:06Long COVID Research - Paxlovid Trial (PAX LC): The Yale study published in Lancet Infectious Diseases found that a 15-day course of Paxlovid did not significantly improve symptoms in individuals with established long COVID compared to placebo, challenging the hypothesis of active viral replication as a primary driver.
36:51Long COVID Research - Brain Volume: A systematic review in NeuroImage suggests patients with more severe initial COVID-19 infections are more likely to have smaller gray matter volumes compared to controls, though findings are inconsistent across studies and brain regions.
38:23Long COVID Research - Donepezil Trial: A randomized clinical trial found Donepezil (Aricept) did not significantly improve fatigue or psychological symptoms in patients with post-COVID conditions.
39:05Support & Outreach: Reminder about the ongoing fundraiser for Floating Doctors.
40:07Q&A - Penicillin Allergy Deaths: Dr. Griffin clarifies that the widely cited figure of 500-1000 annual US deaths from penicillin anaphylaxis is likely inflated and based on old modeling, not real-world data (UK data suggests ~1 death per 100 million exposures). Emphasizes importance of de-labeling non-allergic patients.
42:39Q&A - Novavax Availability: Listener confirms difficulty finding Novavax; Dr. Griffin reiterates concerns about production, approval status, and low uptake impacting its availability.
44:48Q&A - Measles Booster Need: Confirms individuals born before 1989 likely only received one MMR dose and should get a second for full protection.
45:34Q&A - H5N1 in Flu Vaccine: Explains that adding H5N1 isn't currently planned; it requires a licensed vaccine matching circulating strains and a higher perceived public health threat level.
46:54Q&A - Measles Vaccine Non-Responders: Discusses the complexity, noting that "non-responder" status is usually based on antibody levels, which doesn't capture potential T-cell immunity. Hereditary links are unclear.
47:40Q&A - Misinformation Encounter: Listener shares an anecdote about a pharmacist downplaying the measles outbreak, highlighting the challenge of combating misinformation and public complacency.
49:27Conclusion: The episode ends, underscoring the ongoing "failure to communicate" effectively about public health risks and interventions.